Artificial Intelligence Having a Real Impact on Healthcare
Author: Ling Han
September 24, 2026
Artificial intelligence (AI) has been the dominant theme in equity markets throughout 2026. Investors have largely focused on the hyper-scalers and their enormous investments in AI infrastructure. Yet large-cap technology is only part of the story as AI is reshaping industries across sectors.
This edition of AI in Focus puts healthcare in the spotlight.
While many of the use cases for artificial intelligence remain quite speculative in nature, the healthcare sector is already benefitting from this widespread technological revolution in two meaningful ways: drug development and diagnostics.
Right now, it costs pharmaceutical companies billions of dollars to develop new drugs. AI provides a direct avenue to cut costs by meaningfully expediting the discovery process while also facilitating the automation of some costly and time-consuming preclinical work.
AI’s impact on diagnostics may be even more profound as it shifts the industry away from old hardware towards interlocking intelligent platforms. Applying artificial intelligence to standard CT scans and MRIs is already helping clinicians detect anomalies and lesions that would have otherwise gone undetected by human eyes.
Surgical robots are another beneficiary of AI as algorithms and data-trained models are improving their perception, navigation, and decision-making. While we are still a long way away from having robots conduct fully autonomous procedures, meaningful advancements are being made in telesurgery—doctors performing operations remotely from somewhere other than the actual hospital.
So, with all these technologies gaining traction at such a rapid pace, where might investors interested in healthcare find opportunities?
We believe one sub-sector to watch could be precision oncology, which is the use of patient-specific genetic and molecular data to improve cancer detection, diagnosis, and treatment. Standardized screening procedures only exist for a few of the 200-plus known types of cancer; there are potential opportunities for AI-powered personalized diagnostics.
The picks and shovels of the drug development space could also be worth watching, particularly life science tool companies that support large data set generation as well as AI model validation across the broader healthcare ecosystem. This represents a more diversified way to gain exposure to the theme, as demand for these services may grow regardless of which developers ultimately prove most successful.
In terms of metrics for analysis, top-line sales growth and margin could remain key differentiators. Return on invested capital has also become increasingly important with the volume and speed of acquisitions trending upward over the past year.
The impetus for this expansion is the revenue cliff that the industry is staring down within the next three-to-five years. It has created a sense of urgency amongst the major players to acquire later-stage biotech companies to help fill that gap, and with pressure comes the potential for overpriced acquisitions that may hurt the bottom line.
While optimism is certainly warranted, the narrative that artificial intelligence will cure all diseases is more of a pipe dream than reality. AI is still largely a research and productivity tool rather than a fully integrated clinical solution. The pharmaceutical industry is risk-averse by nature; extensive data will be needed to drive further adoption.
Still, healthcare is nonetheless one of the economic sectors in which AI is clearly improving businesses. Further implementation may power continued breakthroughs and cost savings for companies in the coming years—and, most importantly, improve medical outcomes for patients around the world.
The views expressed in this blog are those of the author and do not necessarily represent the opinions of AGF, its subsidiaries or any of its affiliated companies, funds, or investment strategies.
Commentary and data sourced from Bloomberg, Reuters and other news sources unless otherwise noted. The commentaries contained herein are provided as a general source of information based on information available as of September 21st, 2026. It is not intended to address the needs, circumstances, and objectives of any specific investor. The content of this commentary is not to be used or construed as investment advice, as an offer to buy or sell any securities, and is not intended to suggest taking or refraining from any course of action. Every effort has been made to ensure accuracy in these commentaries at the time of publication, however, accuracy cannot be guaranteed. Market conditions may change and AGF Investments accepts no responsibility for individual investment decisions arising from the use or reliance on the information contained herein.
This website may contain links to third-party websites. The parties who own, maintain or control third-party websites are solely responsible for their content, and AGF assumes no responsibility for such content. Links to third-party websites are provided for convenience only and are not to be construed as an endorsement or recommendation of the products, services, advice or information that may be available on them.
This document may contain forward-looking information that reflects our current expectations or forecasts of future events. Forward-looking information is inherently subject to, among other things, risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed herein.
For Canadian investors: Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated.
AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). AGFI is registered as a portfolio manager across Canadian securities commissions. AGFUS is a registered investment advisor with the U.S. Securities Exchange Commission. AGFIA is regulated by the Central Bank of Ireland and registered with the Australian Securities & Investments Commission. The term AGF Investments may refer to one or more of these subsidiaries or to all of them jointly. This term is used for convenience and does not precisely describe any of the separate companies, each of which manages its own affairs.
AGF Investments entities only provide investment advisory services or offers investment funds in the jurisdiction where such firm, individuals and/or product is registered or authorized to provide such services. Investment advisory services for U.S. persons are provided by AGFUS.
® / TM The “AGF” logo and all associated trademarks are registered trademarks or trademarks of AGF Management Limited and used under license.
RO: 20260921-5944046
About AGF Management Limited
Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.
AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and private investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.
Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. AGF serves more than 800,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.
For further information, please visit AGF.com.
© 2026 AGF Management Limited. All rights reserved.
